Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells

Toxicology in Vitro

Volumn 25, Issue 8, 2011, Pages 2113-2119

  Frederick, Douglas M ^a   Jacinto, Erina Y ^a   Patel, Niti N ^a   Rushmore, Thomas H ^a   Tchao, Ruy ^a   Harvison, Peter J ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

3 (3,5 Dichlorophenyl) 2,4 thiazolidinedione; Cytochrome P450; Drug metabolism; HepG2 cells; Thiazolidinedione

Indexed keywords

(3,5 DICHLOROPHENYL)AMINOCARBONYL THIOGLYCOLIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BALANCED SALT SOLUTION; CYTOCHROME P450 3A4; TESTOSTERONE; THIOGLYCOLIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME STABILITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROLYSIS; HYDROXYLATION; LC 50; NUCLEOTIDE SEQUENCE; TOXICITY TESTING;

CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DEXAMETHASONE; ENZYME INHIBITORS; HEP G2 CELLS; HUMANS; HYDROLYSIS; HYPOGLYCEMIC AGENTS; KETOCONAZOLE; STEROID HYDROXYLASES; THIAZOLIDINEDIONES; TRANSFECTION;

ANIMALIA; RATTUS;

EID: 82655173786     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2011.09.015     Document Type: Article

References (36)

1. Alvarez-Sánchez R., Montavon F., Hartung T., Pähler A. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem. Res. Toxicol. 2006, 19:1106-1116.
2. Baughman T.M., Graham R.A., Wells-Knecht K., Silver I.S., Tyler L.O., Wells-Knecht M., Zhao Z. Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab. Dispos. 2005, 33:733-738.
3. Bonkovsky H.L., Azar R., Bird S., Szabo G., Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig. Dis. Sci. 2002, 47:1632-1637.
4. Brown W.E., Green A.H., Cedel T.E., Cairns J. Biochemistry of protein-isocyanate interactions: a comparison of the effects of aryl vs. alkyl isocyanates. Environ. Health Perspect. 1987, 72:5-11.
5. Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005, 41:237-246.
6. Crincoli C.M., Patel N.N., Tchao R., Harvison P.J. Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. Toxicology 2008, 250:100-108.
7. Forman L.M., Simmons D.A., Diamond R.H. Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 2000, 132:118-121.
8. Gitlin N., Julie N.L., Spurr C.L., Lim K.N., Juarbe H.M. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann. Intern. Med. 1998, 129:36-38.
9. Gouda H.E., Khan A., Schwartz J., Cohen R.I. Liver failure in a patient treated with long-term rosiglitazone therapy. Am. J. Med. 2001, 111:584-585.
10. Graham D.J., Green L., Senior J.R., Nourjah P. Troglitazone-induced liver failure: a case study. Am. J. Med. 2003, 114:299-306.
11. He K., Talaat R.E., Pool W.F., Reily M.D., Reed J.E., Bridges A.J., Woolf T.F. Metabolic activation of troglitazone: identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 2004, 32:639-646.
12. Kassahun K., Pearson P.G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., Baillie T.A. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 2001, 14:62-70.
13. Kennedy E.L., Tchao R., Harvison P.J. Nephrotoxic and hepatotoxic potential of imidazolidinedione-, oxazolidinedione- and thiazolidinedione-containing analogues of N-(3,5-dichlorophenyl)succinimide (NDPS) in Fischer 344 rats. Toxicology 2003, 186:79-91.
14. Kohlroser J., Mathai J., Reichheld J., Banner B.F., Bonkovsky H.L. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J. Gastroenterol. 2000, 95:272-276.
15. Macháček V., Štěrba V., Zahradníčková H. Solvolysis kinetics and mechanism of 3-methyl-1,3-thiazolidine-2,4-dione. Coll. Czech. Chem. Commun. 1981, 46:3097-3103.
16. Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann. Intern. Med. 2001, 135:306.
17. Marcy T.R., Britton M.L., Blevins S.M. Second-generation thiazolidinediones and hepatotoxicity. Ann. Pharmacother. 2004, 38:1419-1423.
18. May L.D., Lefkowitch J.H., Kram M.T., Rubin D.E. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med. 2002, 136:449-452.
19. Moore J.T., Collins J.L., Pearce K.H. The nuclear receptor superfamily and drug discovery. Chem. Med. Chem. 2006, 1:504-523.
20. Naspinski C., Gu X., Zhou G.D., Mertens-Talcott S.U., Donnelly K.C., Tian Y. Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. Toxicol. Sci. 2008, 104:67-73.
21. Patel N.N., Crincoli C.M., Kennedy E.L., Frederick D.M., Tchao R., Harvison P.J. Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats. Xenobiotica 2008, 38:435-449.
22. Patel, N.N., Crincoli, C.M., Frederick, D.M., Tchao, R., Harvison, P.J., in press. Effect of structural modifications on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. J. Appl. Toxicol. doi:10.1002/jat.1639.
23. Rodríguez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., Gómez-Lechón M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 2002, 32:505-520.
24. Rushmore T.H., Pickett C.B. Xenobiotic responsive elements controlling inducible expression by planar aromatic compounds and phenolic antioxidants. Methods Enzymol. 1991, 206:409-420.
25. Rushmore T.H., Morton M.R., Pickett C.B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 1991, 266:11632-11639.
26. Rushmore T.H., Reider P.J., Slaughter D., Assang C., Shou M. Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab. Eng. 2000, 2:115-125.
27. Saha S., New L.S., Ho H.K., Chui W.K., Chan E.C. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity. Toxicol. Lett. 2010, 192:141-149.
28. Scheen A.J. Thiazolidinediones and liver toxicity. Diabetes Metab. 2001, 27:305-313.
29. Schuetz E.G., Wrighton S.A., Barwick J.L., Guzelian P.S. Induction of cytochrome. P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de novo synthesis of a common form of cytochrome P-450 in cultures of adult rat hepatocytes and in the liver in vivo. J. Biol. Chem. 1984, 259:1999-2006.
30. Swales K., Plant N., Ayrton A., Hood S., Gibson G. Relative receptor expression is a determinant in xenobiotic-mediated CYP3A induction in rat and human cells. Xenobiotica 2003, 33:703-716.
31. Tettey J.N., Maggs J.L., Rapeport W.G., Pirmohamed M., Park B.K. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 2001, 14:965-974.
32. Vignati L., Turlizzi E., Monaci S., Grossi P., Kanter R., Monshouwer M. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 2005, 216:154-167.
33. Yamamoto Y., Nakajima M., Yamazaki H., Yokoi T. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci. 2001, 70:471-482.
34. Yamamoto Y., Yamazaki H., Ikeda T., Watanabe T., Iwabuchi H., Nakajima M., Yokoi T. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 2002, 30:155-160.
35. Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F.P., Yokoi T. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 1999, 27:1260-1266.
36. Yoshitomi S., Ikemoto K., Takahashi J., Miki H., Namba M., Asahi S. Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol. In Vitro. 2001, 15:245-256.